Abstract
The recent development of new oral anticoagulants, of which dabigatran etexilate is currently at the most advanced stage of development, is the greatest advance in the provision of convenient anticoagulation therapy for many years. A new oral anticoagulation treatment, dabigatran etexilate, is already on the market in Europe. The main interest probably will be to improve the prescription and the adherence to an effective thromboprophylaxis in medical conditions such as atrial fibrillation without bleeding side effects, without the need for monitoring coagulation, and without drug and food interactions such as vitamin K anticoagulant (VKA) treatment. Dabigatran is particularly interesting for extended thromboprophylaxis after major orthopedic surgery in order to avoid daily injection for a month. However, oral long-term treatments such as VKA are not systematically associated with a higher compliance level than injected treatments such as low-molecular-weight heparins. Indeed, adherence to an oral treatment, instead of the usual daily injection in major orthopedic surgery, is complex, and based not only on the frequency of dosing but also on patient motivation, understanding, and socio-economic status. New oral anticoagulants ma...Continue Reading
References
Apr 1, 1992·Mayo Clinic Proceedings·S B MooreH F Taswell
Jun 9, 1989·JAMA : the Journal of the American Medical Association·J A CramerV L Ouellette
Mar 1, 1994·Annals of Hematology·A LorentzC Kruse
Aug 23, 1993·Archives of Internal Medicine·R I Horwitz, S M Horwitz
Aug 1, 1993·Chest·J A Cramer
May 15, 1993·Cancer·C K Tebbi
Oct 1, 1996·Research in Nursing & Health·E C Devine
May 1, 1997·British Journal of Anaesthesia·H Kehlet
Jul 1, 1997·The American Journal of Medicine·J H ArnstenD E Singer
Oct 7, 1997·Diabetes Care·A H PaesC J Soe-Agnie
Nov 5, 1997·British Journal of Haematology·F J van der MeerF R Rosendaal
Aug 10, 2000·Italian Journal of Neurological Sciences·U ScodittiD Mancia
Mar 8, 2003·Thrombosis and Haemostasis·Silvy LaportePatrick Mismetti
Jul 23, 2004·Thrombosis and Haemostasis·Bengt I ErikssonUNKNOWN METHRO III Study Investigators
Jan 7, 2005·Journal of Thrombosis and Haemostasis : JTH·B I ErikssonUNKNOWN BISTRO II Study Group
Aug 17, 2005·Journal of Thrombosis and Haemostasis : JTH·N RosencherUNKNOWN ESCORTE group
Nov 25, 2005·Pharmacotherapy·Ian A Orensky, David A Holdford
Jan 31, 2006·Archives of Physical Medicine and Rehabilitation·Devora LiebermanDavid Lieberman
Sep 2, 2006·Clinical Rehabilitation·Nicolai B FossHenrik Kehlet
Nov 14, 2006·Chest·Ann K WittkowskyVikrant Vats
May 1, 2007·Journal of Rehabilitation Medicine·Michael StenvallYngve Gustafson
Sep 18, 2007·Lancet·Bengt I ErikssonUNKNOWN RE-NOVATE Study Group
Jul 24, 2008·Chest·William H GeertsClifford W Colwell
Citations
Jun 29, 2011·Journal of Thrombosis and Thrombolysis·Lauren Garton, Joseph F Crosby
Nov 20, 2013·Musculoskeletal Surgery·W Klauser, M Dütsch
Aug 22, 2013·Journal des maladies vasculaires·J YverUNKNOWN les membres du réseau GRANTED
Jul 6, 2014·Mayo Clinic Proceedings·Saurav ChatterjeeDebabrata Mukherjee
Feb 14, 2013·Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen·S RübenackerM Guschmann
Oct 21, 2015·BMJ Open·G Sanfélix-GimenoS Peiró
Nov 23, 2015·International Journal of Cardiology·Prasad S NishtalaSarah N Hilmer
Jan 21, 2015·Pacing and Clinical Electrophysiology : PACE·Yu-Feng HuShih-Ann Chen
Mar 6, 2012·Orthopaedics & Traumatology, Surgery & Research : OTSR·B LebelC Vielpeau
Mar 17, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Shannon CopeJeroen P Jansen
Aug 6, 2011·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Matthew L Blommel, Amy L Blommel
Jun 15, 2021·Frontiers in Pharmacology·Roberta RobertiRita Citraro